We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-17.59%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
-$301M
Cap. Flow
+$247M
Cap. Flow %
16.82%
Top 10 Hldgs %
53.54%
Holding
70
New
19
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$84.4M
2
SAGE
Sage Therapeutics
SAGE
+$68.5M
3
BDTX icon
Black Diamond Therapeutics
BDTX
+$61.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$55.7M
5
AMRN
Amarin Corp
AMRN
+$37.4M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$82.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$29M
3
APLS
Apellis Pharmaceuticals
APLS
+$24.5M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$23.5M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LABD icon
26
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
$17.6M 1.2%
6,250
-8,175
-57% -$23.3M
CGEN icon
27
Compugen
CGEN
$222M
$17.3M 1.18%
+2,383,673
New +$18.7M
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
$16.5M 1.12%
+4,075,000
New +$15.4M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.43B
$15.6M 1.07%
+370,000
New +$15.2M
JJT
30
PUT
DELISTED
iPath Series B Bloomberg Tin Subindex Total ReturnSM ETN
JJT
$13.9M 0.95%
+300,000
New +$12.6M
PRVL
31
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$13.7M 0.93%
1,123,105
– –
GBT
32
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.8M 0.87%
250,000
– –
NGNE icon
33
Neurogene
NGNE
$656M
$11.5M 0.78%
50,463
– –
CABA icon
34
Cabaletta Bio
CABA
$437M
$11.4M 0.78%
1,566,361
– –
RLMD icon
35
Relmada Therapeutics
RLMD
$557M
$10.2M 0.7%
300,000
– –
AGEN
36
Agenus
AGEN
$312M
$9.8M 0.67%
+203,800
New +$12.8M
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$9.74M 0.66%
1,200,000
– –
AMRN
38
Amarin Corp
AMRN
$299M
$9M 0.61%
+112,500
New +$37.4M
AKRO
39
DELISTED
Akero Therapeutics
AKRO
$8.83M 0.6%
416,495
-66,000
-14% -$1.42M
AXSM icon
40
Axsome Therapeutics
AXSM
$11.2B
$8.82M 0.6%
+150,000
New +$12.2M
KURA icon
41
Kura Oncology
KURA
$800M
$8.41M 0.57%
844,789
– –
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.69B
$7.96M 0.54%
725,782
+475,782
+190% +$4.46M
RNAC icon
43
Cartesian Therapeutics
RNAC
$229M
$7.92M 0.54%
109,469
– –
KOD icon
44
Kodiak Sciences
KOD
$2.6B
$7.16M 0.49%
+150,000
New +$9M
MTNB icon
45
Matinas BioPharma
MTNB
$1.88M
$6.89M 0.47%
229,573
+25,807
+13% +$1.56M
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.06B
$6.8M 0.46%
+600,000
New +$8.54M
LITS
47
Lite Strategy Inc
LITS
$32.8M
$4.69M 0.32%
145,655
– –
TARA icon
48
Protara Therapeutics
TARA
$220M
$4.59M 0.31%
+199,567
New +$5.81M
KNSA icon
49
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.5M 0.31%
290,577
– –
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$6.46B
$4.44M 0.3%
317,000
– –
1
2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Boxer Capital held 70 positions worth $1.47B, down 17% from $1.77B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $247M of net new capital in Q1 2020, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Revolution Medicines: 3,049,764 shares worth $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, an estimated $23.5M trimmed.

  • Boxer Capital's largest Q1 2020 buy was Revolution Medicines: 3,049,764 shares worth $66.8M.
  • Boxer Capital added most to Sage Therapeutics in Q1 2020, an estimated $68.5M increase.
  • Boxer Capital's biggest Q1 2020 reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, cutting an estimated $23.5M.
  • Boxer Capital fully exited Medicines Co in Q1 2020, selling an estimated $82.1M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.47B portfolio in Q1 2020.
  • Boxer Capital opened 19 new positions and closed 8 in Q1 2020.
  • Boxer Capital's portfolio value fell 17% quarter-over-quarter to $1.47B.

Based on Boxer Capital's 13F filing for Q1 2020, filed 15 May 2020.